1. Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial. (14th November 2018) Authors: Urbonas, V; Schadendorf, D; Zimmer, L; Danson, S; Marshall, E; Corrie, P; Wheater, M; Plummer, E; Mauch, C; Scudder, C; Goff, M; Love, S B; Mohammed, S B; Middleton, M R Journal: Annals of oncology Issue: Volume 30:Number 2(2019) Page Start: 317 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗